Small molecule · Activator of glucokinase (GCK) · developed by vTv Therapeutics
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator that acts as an adjunct to insulin. It is studied in type 1 and type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06334133 | Phase 3 | Diabetes Mellitus, Type 1 | Active not recruiting | VTVT |
| NCT03335371 | Phase 1/2 | Diabetes Mellitus, Type 1 | Completed | VTVT |
| NCT02405260 | Phase 2 | Diabetes Mellitus, Type 2 | Completed | VTVT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Updated Nov 1, 2026. Something wrong or missing? Report it on the VTVT page.
See VTVT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VTVT catalysts and pipeline →